arrow
I

Ivetta Danylesko

Sheba Medical Center
H指数:22
被引数:1,501

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous hematopoietic stem cell transplantation: a case series

抗CD19 CAR-T细胞疗法作为自体造血干细胞移植后系统性硬化症复发的挽救治疗:一项病例系列研究

2026-04-040
PRE
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia

CD19 CAR T细胞疗法在Richter转化中的研究:欧洲慢性淋巴细胞白血病研究倡议进行的 multicentre 回顾性分析

2025-10-220
OAAI
Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)—An open-label, phase I/II study

Bisantrene联合Fludarabine和Clofarabine作为成人难治性或复发性急性髓系白血病(AML)的挽救治疗方案——一项开放标签、I/II期研究

2025-08-010
PRE
Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

弥漫大B细胞淋巴瘤复发或难治性情况下对CAR-T疗法的肿瘤决定因素

BLOOD
IF23.1
2024-11-050
PRE
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma
2024-06-203
OAAI
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma

大b细胞淋巴瘤中嵌合抗原受体T细胞治疗后的异基因造血细胞移植

2023-02-0116
PRE
P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE

P1400: 接受抗CD19 CAR-T细胞治疗的原发性纵隔B细胞淋巴瘤患者三年结局——一项单中心经验

2023-01-010
OA
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
LEUKEMIA
IF13.4
2022-11-0536
OA
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning
2017-07-1913
OAAI